Targeting Src homology phosphatase 2 ameliorates mouse diabetic nephropathy by attenuating ERK/NF-κB pathway-mediated

Che Yu1,2,3, Zhuo Li1, Cuili Nie4

  • 1Department of Nephrology, Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, China.

Insights

Inhibition of SHP2 (Src homology phosphatase 2) reduces kidney inflammation in diabetic nephropathy (DN). This study highlights SHP2 as a potential therapeutic target for DN treatment.

Area of Science:

  • Biochemistry
  • Immunology
  • Pathophysiology

Background:

  • Diabetic nephropathy (DN) involves significant renal inflammation.
  • The role of Src homology phosphatase 2 (SHP2) in DN pathogenesis is not well understood.
  • SHP2 is implicated in diabetes-related inflammation.

Discussion:

  • SHP2 activity is elevated in DN patients and db/db mice.
  • Pharmacological inhibition of SHP2 using PHPS1 ameliorates DN and reduces renal inflammation in mice.
  • PHPS1 treatment inhibits high glucose-induced inflammatory responses in HK-2 cells.

Key Insights:

  • SHP2 inhibition suppresses the ERK/NF-κB signaling pathway, a key mediator of inflammation.
  • PHPS1 effectively blocks the activation of the ERK/NF-κB pathway in both in vitro and in vivo models of DN.
  • SHP2 activity positively correlates with ERK/NF-κB activation in DN patients.

Outlook:

  • SHP2 represents a promising therapeutic target for diabetic nephropathy.
  • Pharmacological inhibition of SHP2 offers a potential strategy for mitigating DN progression.
  • Further research into SHP2-targeted therapies could lead to novel treatments for DN.